High Frequency of Specific Polysaccharide Antibody Deficiency in Adults With Unexplained, Recurrent and/or Severe Infections With Encapsulated Bacteria.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Stabler Sarah, Lamblin Catherine, Gaillard Sacha, Just Nicolas, Mihailescu Mirela, Viget Nathalie, Sy Ndiaye Thierno, Dzeing Ella Arnaud, Brunin Guillaume, Weyrich Pierre, Prevotat Anne, Chenivesse Cécile, Le Rouzic Olivier, Mortuaire Geoffrey, Vuotto Fanny, Faure Karine, Leurs Amélie, Wallet Frédéric, Loiez Caroline, Titecat Marie, Le Guern Rémi, Hachulla Eric, Sanges Sébastien, Etienne Nicolas, Terriou Louis, Launay David, Lopez Benjamin, Bahuaud Mathilde, Batteux Frédéric, Dubucquoi Sylvain, Gesquière-Lasselin Cyrielle, Labalette Myriam, Lefèvre Guillaume, DIPANOR network
Аннотация
METHODS: In this prospective multicenter study, inclusion criteria were recurrent benign upper and lower respiratory tract infections (RTIs) for at least two years (group 1), at least one upper or lower RTI requiring hospitalization (group 2), and/or at least one invasive infection documented with encapsulated bacteria (group 3). Main exclusion criteria were all local and general conditions that could explain infections. If no PID diagnosis was made, response to polysaccharide antigens was assessed using a pneumococcal polysaccharide vaccine.
RESULTS: From March 2015 to March 2020, 118 patients were included (37 males, median age of 41 years): 73, 17, and 28 in groups 1, 2, and 3, respectively. Forty-seven PIDs were diagnosed, giving an estimated frequency of 39.8% (95% confidence interval [CI] [30.4, 48.8]). SPAD was the most frequent diagnosis by far (n = 37/47, 78.7%), and was made in 23, 5, and 9 patients from groups 1 to 3, respectively. All SPAD patients received conjugate vaccines and, according to their infectious history, were on surveillance or treated with preventive antibiotics (n = 6) and/or with immunoglobulins replacement therapy (n = 10), the latter being dramatically efficient in all cases.
CONCLUSIONS: Considering its high prevalence among adults with unexplained recurrent and/or severe bacterial infections, SPAD should be screened in those patients.
CLINICAL TRIALS REGISTRATION: NCT02972281.